View Cart  

EMA Draft Guideline Suggests Primary Efficacy Parameters for MS Drugs

A A
Drugmakers evaluating multiple sclerosis treatments for the EU should use relapse rate as the primary efficacy parameter in clinical trials for relapsing-remitting MS or secondary progressive MS with superimposed relapses, according to a draft European Medicines Agency (EMA) guideline.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00